Acute Hereditary Angioedema With Airway Compromise: Avoiding Airway Intervention With C1 Inhibitor Concentrate
Immunology and Immunogenetics Insights · 2018
DOI: 10.1177/1178634518786254 ↗Kurz gefasst
Fachartikel in der Zeitschrift Immunology and Immunogenetics Insights, 2018. Verfasst von WeiZhong Ernest Fu und 2 weiteren Autor:innen. Die Arbeit nennt 10 Literaturangaben.
Abstract (Originalsprache)
Introduction
Hereditary angioedema (HAE) is an autosomal dominant disease caused by deficiency of the plasma protein C1 inhibitor (C1-INH). Patients classically present with recurrent localized subcutaneous or submucosal edema lasting for 2 to 5 days, severe abdominal pain, or acute airway obstruction which can be fatal. Case presentations: We highlight 2 patients with acute airway compromise secondary to HAE who were successfully treated with plasma-derived C1-INH concentrates.
Conclusions
The timely administration of plasma-derived C1-INH concentrates for the acute treatment of HAE has been proven to be effective in both patients in aborting an airway complication. A high index of suspicion is required for the early diagnosis and treatment of this potentially fatal condition.
Zitieren
APA
Fu, W. E., Tan, S., & Ho, E. C. (2018). Acute Hereditary Angioedema With Airway Compromise: Avoiding Airway Intervention With C1 Inhibitor Concentrate. Immunology and Immunogenetics Insights. https://doi.org/10.1177/1178634518786254
Vancouver
Fu WE, Tan S, Ho EC. Acute Hereditary Angioedema With Airway Compromise: Avoiding Airway Intervention With C1 Inhibitor Concentrate. Immunology and Immunogenetics Insights. 2018. doi:10.1177/1178634518786254
BibTeX
@article{Fu2018,
author = {Fu, WeiZhong Ernest and Tan, Sze-Chin and Ho, Eu Chin},
title = {Acute Hereditary Angioedema With Airway Compromise: Avoiding Airway Intervention With C1 Inhibitor Concentrate},
journal = {Immunology and Immunogenetics Insights},
year = {2018},
doi = {10.1177/1178634518786254}
}
EUVIMED